Congratulations to Kiadis Pharma on recently announcing that it is being acquired by Sanofi in a deal valued at approximately €308m ($359m), a 272% premium over last week’s closing price, one of the largest premiums in European biotech. After the discontinuation of its lead product candidate and subsequent reorganization in 2019, Kiadis started 2020 as an entirely new company […]
Has Kiadis Found Immunotherapy’s Killer App? In Amsterdam, there has just been a glimpse of the future of cellular medicine.
Amsterdam, The Netherlands, 22 October 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts in the field of oncology and cell therapy. The SAB will provide invaluable scientific expertise and […]
